
Moderna’s Next $20B Franchise – Learning From Merck’s Keytruda (NYSE:MRK)
asbe/iStock via Getty Images Investment Thesis It might seem a stretch to assume that Moderna’s (NASDAQ:MRNA) mRNA-4157 (or any other oncology pipelines) would achieve the same success as Merck & Co’s (NYSE:MRK) Keytruda. However, we […]